Concurrent bevacizumab (BEV) with biochemotherapy (BC) followed by ipilimumab for advanced melanoma: A phase I-II trial.
David R. Minor
Consultant or Advisory Role - Genentech/Roche
Honoraria - Genentech/Roche
Wei Wang
No relevant relationships to disclose
Mohammed Kashani-Sabet
No relevant relationships to disclose